{"id":"W4399361197","doi":"10.1007/s10637-024-01448-w","title":"A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; Centre Hospitalier de l’Université de Montréal; Crosslight Software (Canada); University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Nausea; Adverse effect; Medicine; Vomiting; Pharmacokinetics; Internal medicine; Pharmacology; Gastroenterology; Refractory (planetary science); Dosing; Tolerability; Toxicity; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001331929,0.001829861,0.001696504,0.0004627416,0.0005042929,0.0008313876,0.0007839493,0.0009921805,0.002947834],"category_scores_gemma":[0.0007218128,0.0007370984,0.001017806,0.0003477288,0.001075636,0.0008475916,0.0003660721,0.002805648,0.0007794942],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008432596,"about_ca_system_score_gemma":0.001281764,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009756191,"about_ca_topic_score_gemma":0.00261853,"domain_scores_codex":[0.9996901,0.0001385414,0.00001482979,0.00005959671,0.00002252736,0.00007447146],"domain_scores_gemma":[0.9993969,0.00009663879,0.00008787095,0.00004958652,0.00003591729,0.0003331106],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7106654,0.1061749,0.007218033,0.000703004,0.0009758084,0.0006397055,0.0004998227,0.004043802,0.07398875,0.0004266713,0.006913374,0.08775068],"study_design_scores_gemma":[0.4476393,0.533022,0.009393743,0.00002428818,0.0002753031,0.0003327207,0.00007684788,0.001562281,0.004330042,0.0002752725,0.003036409,0.00003174949],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914807,0.001378188,0.0005862659,0.0003584559,0.00009180475,0.003078992,0.001136271,0.0001179224,0.001771376],"genre_scores_gemma":[0.9865096,0.001538398,0.001859776,0.0008324992,0.0001597901,0.003069049,0.002649631,0.00003935704,0.003341855],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002947834,"threshold_uncertainty_score":0.009861469,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008491999688964535,"score_gpt":0.2465649185336351,"score_spread":0.2380729188446706,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}